Identification of targets and new developments in the treatment of multiple sclerosis--focus on cladribine.

Article Details

Citation

Warnke C, Wiendl H, Hartung HP, Stuve O, Kieseier BC

Identification of targets and new developments in the treatment of multiple sclerosis--focus on cladribine.

Drug Des Devel Ther. 2010 Jul 21;4:117-26.

PubMed ID
20689698 [ View in PubMed
]
Abstract

Orally available disease-modifying drugs for relapsing-remitting multiple sclerosis (MS) represent an unmet need for this chronic and debilitating disease. Among 5 currently investigated drugs at phase 3 clinical stage, promising efficacy data for fingolimod and oral cladribine have recently been published. However, benefits need to be weighed against the risks to define the role of these compounds within current treatment regimens. In this review, data on the efficacy of a promising compound, oral cladribine, are discussed and balanced with known and anticipated risks in a postmarketing era, and finally gives an outlook on the potential place of this drug in treatment algorithms for MS in the future.

DrugBank Data that Cites this Article

Drugs
Drug Enzymes
DrugEnzymeKindOrganismPharmacological ActionActions
CladribineDeoxycytidine kinaseProteinHumans
Unknown
Substrate
Details